Skip to search formSkip to main contentSkip to account menu

PF 04929113

Known as: SNX-5422 Mesylate, PF04929113, SNX-5422 
The orally bioavailable mesylate salt of a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BenzamidesIndazoles
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Hsp 90 inhibitor induces KG1 a cell differentiation and apoptosis via Akt / NF-κ B signaling
Heat-shock protein 90 (Hsp 90) acts as a molecular chaperone that maintains protein stability and regulates cell proliferation… 
2014
2014
A Phase IB Dose-Escalation Study of the HSP90 Inhibitor SNX-5422 and Erlotinib in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Poster presented at the 2014 Annual Meeting of the European Society for Medical Oncology in Madrid, Spain, 26-30 September 2014 w… 
2013
2013
Kinases Essential for Male Fertility Serine / Threonine Kinases , a Family of Stabilize and Activate the Testis-specific Heat Shock Protein 90 Functions to Signal Transduction :
2010
2010
Abstract 4512: The novel HSP90 inhibitor, PF-04929113, inhibits AR activity and osteoclastogenesis and delays castrate-resistant LNCaP prostate cancer tumor growth
2009
2009
Cancer Therapy : Preclinical CUDC-305 , a Novel Synthetic HSP 90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
Purpose:We designed and synthesized CUDC-305, an HSP90 inhibitor of the novel imidazopyridine class. Here, we report its unique… 
2009
2009
Abstract #5443: Pharmacokinetics (PK) of PF-04929113 (SNX5422), an orally bioavailable heat shock protein 90 (Hsp90) inhibitor after single and multiple dose administration in patients with…
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO Introduction: Hsp90 inhibitors have the potential for broad anti-cancer…